4 results about "High mortality" patented technology

Cardiac arrest (CA) and traumatic brain injury (TBI) are critical medical events associated with high mortality and long-term disability, primarily due to ischemia and subsequent inflammation. Targeted temperature management (TTM), particularly hypothermia, has proven beneficial in reducing cell death, preserving brain function, and mitigating inflammation following these events. Conventional TTM methods are limited by delayed temperature reduction, poor temperature maintenance, and risks such as thromboembolism. The present invention addresses these challenges by introducing novel devices, apparatus, and systems for extracorporeal whole blood cooling, enabling rapid, controlled induction and maintenance of therapeutic hypothermia. By efficiently cooling the patient's whole blood volume outside the body, the method of the present invention offers a safer, more effective alternative to traditional methods, significantly improving patient outcomes after events such as CA and TBI. The present invention represents a promising advancement in emergency and critical care, enhancing survival and neurological recovery in severely ill patients.

Subphenotypes of MODS associated with poor prognosis have been identified using multiomics analysis of pediatric patients with and without sepsis. Compositions and methods for the diagnosis and management of severe MODS are disclosed.

The invention discloses application of flunarizine in construction of a premature ovarian failure animal model, belongs to the technical field of animal model construction, and creatively utilizes flunarizine to construct the premature ovarian failure animal model which is simple and convenient to operate and stable in phenotype. The model overcomes the defect of high death rate of a traditional chemotherapy model, the model is free of death, and a standardized tool is provided for POF pathogenesis research and drug screening; through multi-dimensional verification of ELISA, histopathology and the like, the model group shows typical ovarian function decline characteristics, and is suitable for reproductive toxicology research and therapeutic drug development.

This invention relates to a progressive pathological animal model for drug evaluation and its construction method, belonging to the field of experimental animal model technology. Addressing the shortcomings of existing models, such as their inability to simulate progressive clinical disease courses, low model success rate, large individual variability, and low fit with clinicopathological features, this invention employs a sequential three-stage synergistic induction modeling method. This method sequentially induces basal metabolic abnormalities, subclinical cardiorenal injury, and progressive cardiorenal fibrosis, accurately matching the natural course of human diseases. This method is simple to operate, requires no complex surgery, and produces a model with a high model success rate, low mortality rate, good uniformity, and a high degree of fit between pathological features and clinical findings. It can be used for screening drugs for the treatment of this disease, evaluating drug efficacy, and studying the mechanism of action.